Xspray Pharma appoints Chief Commercial Officer to drive upcoming Dasynoc™ US product commercialization

Press release 2023-09-15

Xspray Pharma is pleased to announce the appointment of Edward P. Jordan as Chief Commercial Officer. Mr. Jordan will lead the US product launch and commercialization of Dasynoc™, the company’s leading product, with an anticipated launch in September 2024, subject to FDA approval.

This milestone appointment follows Xspray Pharma’s recent settlement of its patent litigation with BMS, facilitating the anticipated early market introduction in 2024. With a storied career, Mr. Jordan boasts a commendable track record, having successfully commercialized and launched numerous pharmaceutical products in the US market, many of which pertain to related oncology indications.

Assuming his new role effective today, September 15, Mr. Jordan transitions from his recent position as Chief Commercial Officer at Humanigen Inc., a US-based biotech firm focusing on oncology and COVID-19 immunotherapies.

“I'm honored to join the Xspray team at this critical juncture. The potential approval of Dasynoc™ aims to bolster the clinical efficiency of dasatinib, benefiting a wider patient demographic by supporting the concomitant use of PPIs for those battling chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL)," stated Edward P. Jordan.

In this pivotal role, Mr. Jordan will team up with Xspray Pharma’s US commercialization partner, Eversana. Together, they'll prepare for the successful commercialization of Dasynoc™ where he will leverage a solid history of collaborating with Eversana. Mr. Jordan's will also helm the commercial introduction of other products in Xspray Pharma's pipeline, capitalizing on the company's patented amorphous technology platform while building the US infrastructure.

Per Andersson, CEO of Xspray Pharma, remarks, “We’re thrilled to onboard such a seasoned professional as Ed to our Xspray team. As we anticipate the market release of Dasynoc™, our flagship product, we’re confident in its potential to pioneer a line of enhanced PKI-products in the US market.”

The launch remains subject to the final approval from the FDA.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with numerous product candidates in clinical development, utilizing its innovative, patented HyNap-technology to create improved versions of marketed protein kinase inhibitors (PKI), the largest oncology segment often with high drug prices. The company's goal is to become a market leader of enhanced PKIs for cancer treatment. Xspray Pharma's primary drug candidate, Dasynoc (XS004-dasatinib), is currently undergoing FDA review. It is an amorphous form of dasatinib, demonstrating bioequivalence at a 30% lower dose because of better solubility profile. Its compatibility with proton pump inhibitors (PPIs), commonly co-prescribed to chronic myeloid leukemia patients, provides a significant advantage. Xspray Pharma is building a robust product portfolio, including XS003-nilotinib (an optimized version of Tasigna®) and XS008-axitinib (an optimized version of Inlyta®).

Xspray Pharma’s shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com